San Francisco Bay Area biotech stories.
Wednesday, March 2, 2011
European Commission OKs Avastin for one use, rescinds it for another
The European Commission approved the use of the world’s best-selling cancer drug, Avastin, in combination with paclitaxel as a treatment for women with metastatic breast cancer, but rescinded its use with docetaxel.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)